Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment.
about
Pentasaccharides for the treatment of deep vein thrombosisPhosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domainVenous thromboembolic diseaseAntifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiencyPharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin.Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesProspective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity.Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly.Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.Venous thromboembolism prevention in acutely ill nonsurgical patients.Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal InsufficiencyUse of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals.Venous thromboembolism in trauma: an update for the intensive care unit practitioner.Epidural bleeding after ACL reconstruction under regional anaesthesia: a case report.Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.Dosing low molecular weight heparins in kidney disease.A clinician's guide to perioperative bridging for patients on oral anticoagulation.Renal profiles of anticoagulants.Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulantsA new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk.Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads.Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients.Considerations for Systemic Anticoagulation in ESRD.Lumbar puncture in patients using anticoagulants and antiplatelet agents.Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.Rapid point-of-care assay of enoxaparin anticoagulant efficacy in whole blood.Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls.Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial.Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation.Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
P2860
Q24186811-4EB6B7DE-2DF2-4F01-B8C6-0ED06B6AB33FQ24336588-C768D7C5-BDE4-4863-ACEC-71B8269E8A73Q24631121-69CF7554-05A7-48D9-86C7-474CDB81FCDDQ24813384-BEB57580-D879-42EF-9E6F-593497ADF720Q26995027-6115836B-6F07-45B2-AE5F-DD1BAB446405Q33362274-90BD960B-F6BC-451A-B68D-A812FC57D057Q33399576-E66DDFA8-1AE5-4E90-AE03-D158E33575C1Q33401095-3832A2A0-325A-41C3-8099-58F7F703682EQ33569992-C8ED118B-6F19-4F64-A7F5-19F0D2302190Q34035190-7E93F5B9-0C78-48A0-B5D4-002F0C08B971Q34612869-FB5A8D8B-88EC-4D73-A26B-89C4BEDECEB9Q34999668-B1688B94-F70E-4826-9C46-3463AE259AEAQ35825778-ACFB5BC2-ED3C-483B-A836-9E5077CF3235Q36022983-4CCE9DDD-5260-4F9F-A7A3-EDFC4592442CQ36128828-3FA06837-8953-45E8-A9F2-79623CF8E377Q36154876-4620A6FC-0E7D-4A36-8945-46A31F91E274Q36484329-25125791-5812-4755-A06A-4C44B467D3B4Q36603232-30D4685F-9F13-43AC-B908-44F6C68DFA9CQ36634214-3D05F78C-83E4-4085-A0C3-EA0C1C87C73FQ36720728-91BCF6C5-FEE8-49D3-8CEF-F1B16C6A5D35Q37338709-A915B7A5-6D22-4460-BFC3-C3D8AFF00079Q37490581-132B46C9-7AAF-4EA1-AD28-ED51C8786010Q37844143-24DDC29D-8A0D-47B4-86CC-584C946D8DDBQ37867276-43C57DCD-517C-4F4B-B6B6-CAC99B695274Q37867286-6EE490A0-1EA8-4DD3-B112-856C770DF621Q37879330-255689A0-89A4-4352-B135-0176A2C54A3FQ37956637-2C643FE8-0FE0-4FDF-8F63-ECC426160964Q37970791-5BD64466-602A-4B72-8351-21AD6A1821F5Q38041947-E5AF1739-01A7-4B5C-B7B2-8C8332DD45A0Q38168477-5916FFE5-1283-4590-8A2D-EE277E118171Q38464975-C913D191-D04B-487C-94AE-A0516C75CFD8Q38935933-7A7976F2-C81A-4EF9-8687-7F0C9FF30ED8Q40170302-7D375125-157F-4959-97D4-5A26F8FB7E5EQ41460353-B72E5171-693F-48A5-A7FD-F4FA39B976A9Q42658234-74C7FF9F-4189-41FC-98C0-4EE5635F74F5Q43108541-49B5D769-FAB7-492C-8874-9D0BC2542BD5Q44437063-91F98573-F256-4339-9A2F-71502BF976B1Q44904202-2491688A-D1FA-46B0-8D93-DEA47F54A6C2Q44921971-72790558-FF1D-4DD7-844E-69B1AFBCA9CDQ45029803-304E4998-25F3-486F-8399-C4A0DD1C38EB
P2860
Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Pharmacokinetics and pharmacod ...... atients with renal impairment.
@en
Pharmacokinetics and pharmacod ...... atients with renal impairment.
@nl
type
label
Pharmacokinetics and pharmacod ...... atients with renal impairment.
@en
Pharmacokinetics and pharmacod ...... atients with renal impairment.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... atients with renal impairment.
@en
Pharmacokinetics and pharmacod ...... atients with renal impairment.
@nl
P2093
P1433
P1476
Pharmacokinetics and pharmacod ...... atients with renal impairment.
@en
P2093
Bruno X Boutouyrie
Colette G Guimart
Ger-Jan C M Sanderink
Marie-Laure Ozoux
Navinchandra U Jariwala
Umesh A Shukla
P304
P356
10.1016/S0049-3848(02)00031-2
P577
2002-02-01T00:00:00Z